Yuhan Corporation announced on the 30 May that it has signed an in-license agreement with J INTS BIO for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'. The total contract size is $325 million, and it includes an upfront payment of $1.9 million and milestone payments according to future development, permits, and sales. JIN-A04 is an oral TKI targeting non-small cell lung cancer carrying HER2 mutations, and there is currently no approved oral drug approved to date.

Preclinical data of JIN-A04 was recently presented at the 2023 edition of the American Cancer Research Association (AACR) annual meeting in April at Orlando, USA showing strong efficacy in both In-vitro and In-vivo studies.